CDKN2A and neoplasm: To further demonstrate the utility and validate the screening results of SLKG for novel tumor therapy discovery, the top-ranked SL gene pair CDKN2A + RRM2 (ranked 15th among the 155 curated SL) was selected as a demonstrating experimental validation for in vitro verification.